Dendritic cells generated from CD34+ progenitor cells with flt3 ligand, c-Kit ligand, GM-CSF, IL-4, and TNF-α are functional antigen-presenting cells resembling mature monocyte-derived dendritic cells

Journal of Immunotherapy

Volumn 23, Issue 1, 2000, Pages 48-58

  Ferlazzo, Guido ^a   Klein, Jared ^a   Paliard, Xavier ^b   Wei, Wei Zen ^a   Galy, Anne ^a,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; CD34; Dendritic cells; Monocyte; T lymphocyte activation

Indexed keywords

B7 ANTIGEN; CD1 ANTIGEN; CD14 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; FLT3 LIGAND; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; KEYHOLE LIMPET HEMOCYANIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; STEM CELL FACTOR; TETANUS TOXOID; TUMOR NECROSIS FACTOR;

ANTIGEN PRESENTING CELL; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL GROWTH; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE DIFFERENTIATION; MONOCYTE; PRIORITY JOURNAL; STEM CELL; T LYMPHOCYTE ACTIVATION;

ADULT; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD34; BREAST NEOPLASMS; CELL DIFFERENTIATION; DENDRITIC CELLS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-4; ISOANTIGENS; MEMBRANE PROTEINS; MONOCYTES; SOLUBILITY; STEM CELL FACTOR; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033974938     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200001000-00007     Document Type: Article

References (30)

1. Steinman RM. The dendritic cell system and its role in immunogenicity. Ann Rev Immunol 1991;9:271-96.
2. Hart D. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997;90:3245-87.
3. Flamand V, Sornasse T, Thielemans K, et al. Murine dendritic cells pulsed in vitrowith tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994;24:605-10.
4. Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996;156: 2918-26.
5. Mayordomo J, Zorina T, Storkus W, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297-1302.
6. Hsu FJ, Benike C, Fagnoni F. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-8.
7. Nestle F, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
8. Caux C, Dezutter-Dambuyant C, Schrmitt D, Banchereau J. GM-CSF and TNF-a cooperate in the generation of dendritic Langerhans cells. Nature 1992;360:258-61.
9. Santiago-Schwarz F, Belilos E, Diamond B, Carsons SE. TNF in combination with GM-CSF enhances the differentiation of neonatal cord blood stem cells into dendritic cells and macrophages. J Leukocyte Biol 1992;52:274-81.
10. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992;176:1693-1702.
11. Mackarehtschian K, Hardin JD, Moore KA, et al. Targeted disruption of the Flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 1995;3:147-61.
12. Maraskovsky E, Brasel K, Teepe M, et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 lignad-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 1996;184:1953-62.
13. Siena S, Di Nicola M, Bregni M, et al. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hematol 1995;23:1463-71.
14. Rosenzwajg M, Camus S, Guigon M. Gluckman J. The influence of interleukin (IL)-4, IL-13, and Flt3 ligand on human dendritic cell differentiation from cord blood CD34+ progenitor cells. Exp Hematol 1998;26:63-72.
15. Romani N, Reider DHM, Ebner S. et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996;196: 137-51.
16. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and down-regulated by tumor necrosis factor α. J Exp Med 1994;179: 1109-18.
17. Chen B, Shi Y, Smith J, et al. The role of tumor necrosis factor alpha in modulating the quantity of peripheral blood-derived, cytokine-driven human dendritic cells and its role in enhancing the quality of dendritic cell function in presenting soluble antigens to CD4+ T cells in vitro. Blood 1998;91:4652-61.
18. Santiago-Schwarz F, McCarthy M, Tucci J, Carsons S. Neutralization of tumor necrosis factor activity shortly after the onset of dendritic cell hematopoiesis reveals a novel mechanism for the selective expansion of the CD14-dependent dendritic cell pathway. Blood 1998;92:745-55.
19. Bernhard H, Disis ML, Heimfeld S. et al. Generation of immuno-stimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res 1995;55:1099-1104.
20. Boon T, Coulie P, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997;18:267-8.
21. Paliard X, Lee A, Walker C. RANTES, MIP-1a and MIP-1b are not involved in the inhibition of HIV-1SF33 replication mediated by CD8+ T cell clones. AIDS 1996;10:1317-21.
22. Pinkus G, Pinkus JL, Langhoff E. et al. Fascin, a sensitive new marker for Reed-Sternberg cells of Hodgkin's disease. Evidence for a dendritic or B cell derivation? Am J Pathol 1997;150:543-62.
23. Takamizawa M, Rivas A, Fagnoni F, et al. Dendritic cells that process and present nominal antigens to naive T lymphocytes are derived from CD2+ precursors. J Immunol 1997;158:2134-42.
24. Paliard X, de Waal Malefijt R, Yssel H, et al. Simultaneous production of IL-2, IL-4, and IFN-gamma by activated human CD4+ and CD8+ T cell clones. J Immunol 1988;141:849-55.
25. Lansdorp P, Dragowska W, Mayani H. Ontogeny-related changes in proliferative potential of human hematopoietic cells. J Exp Med 1993;178:787-91.
26. Vormoor J, Lapidot T, Pflumio F, et al. Immature human cord blood progenitors engraft and proliferate to high levels in severe combined immunodeficient mice. Blood 1994;83:2489-97.
27. Caux C, Massacrier C, Vanbervliet B, et al. CD34+ hematopoeitic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor a: II. Functional analysis. Blood 1997;90:1458-70.
28. Macatonia S, Taylor P, Knight S, Askonas B. Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro. J Exp Med 1989;169:1255-64.
29. Mehta-Damani A, Markowicz S, Engleman EG. Generation of antigen-specific CD8+ CTLs from naive precursors. J Immunol 1994;153:996-1002.
30. Kawashima I, Hudson SJ, Tsai V, et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Human Immunol 1998;59:1-14.